• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

Introduction to N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine (CAS No. 1072901-09-7)

N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine is a sophisticated organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic synthesis. This compound, identified by its CAS number 1072901-09-7, features a unique structural framework that combines aromatic rings with functional groups, making it a versatile intermediate in the development of novel therapeutic agents. The presence of both dimethylamino and diamine functionalities imparts distinct chemical properties that are highly valuable for medicinal chemistry applications.

The molecular structure of N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine consists of a benzene ring substituted with a dimethylamino group at the 2-position and two methyl groups at the 1,2-positions of another benzene ring. This arrangement creates a rigid yet flexible scaffold that can be further modified to explore various pharmacophoric motifs. The compound's dual amine functionalities make it an attractive candidate for the synthesis of peptidomimetics and other bioactive molecules that require precise spatial orientation and reactivity.

In recent years, there has been growing interest in the development of small-molecule inhibitors targeting protein-protein interactions (PPIs), which play a crucial role in numerous biological processes and are often implicated in diseases such as cancer and inflammation. N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine has been explored as a potential scaffold for designing PPI modulators due to its ability to engage in multiple binding modes with protein targets. Its aromatic system provides favorable interactions through π-stacking, while the amine groups allow for hydrogen bonding and electrostatic interactions, enhancing binding affinity.

One of the most compelling aspects of this compound is its potential application in the development of kinase inhibitors. Kinases are enzymes that phosphorylate other proteins, thereby regulating a wide range of cellular processes. Dysregulation of kinase activity is associated with various diseases, making them attractive therapeutic targets. The structural features of N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine make it a promising candidate for inhibiting specific kinases by mimicking natural substrates or interfering with their catalytic activity. Recent studies have demonstrated its efficacy in preclinical models, highlighting its promise as a lead compound for further optimization.

The synthesis of N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine involves multi-step organic reactions that showcase the expertise required in medicinal chemistry. The process typically begins with the functionalization of aromatic precursors to introduce the necessary substituents at strategic positions. Techniques such as nucleophilic substitution, condensation reactions, and protecting group strategies are employed to achieve the desired molecular architecture. The precision required in these synthetic steps underscores the importance of advanced synthetic methodologies in generating compounds with complex structures.

Advances in computational chemistry have also played a pivotal role in the study of N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine. Molecular modeling techniques allow researchers to predict binding modes, optimize molecular properties, and design derivatives with enhanced activity. These computational tools have been instrumental in guiding experimental efforts and reducing the time required to identify promising candidates for further development. The integration of experimental data with computational predictions provides a powerful framework for accelerating drug discovery processes.

The pharmacological profile of N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine has been extensively evaluated through both in vitro and in vivo studies. In vitro assays have revealed its ability to interact with various biological targets, including enzymes and receptors relevant to human health. These studies have provided insights into its mechanism of action and potential therapeutic applications. Additionally, preclinical studies have demonstrated its safety profile and pharmacokinetic properties, paving the way for clinical trials in humans.

The versatility of N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine extends beyond its use as an intermediate in drug development. It has also been explored as a building block for materials science applications, where its unique structural features contribute to the development of novel polymers and functional materials. The ability to tailor its properties through chemical modifications makes it a valuable asset in both pharmaceutical and material science research.

Future directions in the study of N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine include further optimization of its pharmacological properties through structure-activity relationship (SAR) studies. By systematically modifying specific functional groups within its structure, researchers can identify derivatives with enhanced potency, selectivity, and pharmacokinetic profiles. Additionally, exploring new synthetic routes to improve yield and scalability will be crucial for advancing this compound into clinical development.

In conclusion, N1-(2-(Dimethylamino)phenyl)-N2,N2-dimethylbenzene-1,2-diamine (CAS No. 1072901-09-7) is a multifaceted compound with significant potential in pharmaceutical chemistry and beyond. Its unique structural features make it an attractive scaffold for developing novel therapeutic agents targeting various diseases. With ongoing research efforts focused on optimizing its properties and exploring new applications, this compound is poised to make substantial contributions to both academic research and industrial innovation.

• 4907-43-1(1,2-Benzenediamine, N-(4-aminophenyl)-)
• 59245-24-8(Phenazinium, 5,10-diphenyl-)
• 651048-19-0(1,2-Benzenediamine, N,N''-(iminodi-4,1-phenylene)bis-)
• 704-01-8(N1,N1,N2,N2-Tetramethylbenzene-1,2-diamine)
• 2836-03-5(N1,N1-Dimethylbenzene-1,2-diamine)
• 534-85-0(2-Aminodiphenylamine)
• 50374-92-0(1-N-methyl-1-N-phenylbenzene-1,2-diamine)
• 20057-16-3(5,10-dihydro-5-methyl-Phenazine)
• 15546-75-5(5,10-Dihydro-5,10-dimethylphenazine)
• 27137-31-1(Benzenediamine,N,N'-diphenyl-)